Evidence map›Paper›PMID 22270258›Full record

Trial reportInvestigational new drugs2012

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

S H Park, M H Ryu, B Y Ryoo, S A Im, H C Kwon, S S Lee, S R Park, B Y Kang, Y K Kang

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Investigational new drugs, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 4 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 4 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Trial
  8. Trial
  9. Review
  10. Molecular Mechanisms and Clinical Implications ofCurrent issues in molecular biology · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.Journal of the National Comprehensive Cancer Network : JNCCN · 2022
    Article
  17. Review
  18. Review
  19. The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2022
    Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 1 country.

S H ParkDivision of Hematology-Oncology, Department of Medicine, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea.
M H Ryu
B Y Ryoo
S A Im
H C Kwon
S S Lee
S R Park
B Y Kang
Y K Kang
University of Ulsan · KRAsan Medical Center · KRDong-A University Hospital · KRKyungpook National University Hospital · KRNational Cancer Center · KRSamsung Medical Center · KRSeoul National University Hospital · KRYonsei University Health System · KR

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

purposeTo evaluated the efficacy and safety of sorafenib in patients with advanced gastrointestinal stromal tumors (GIST) who failed to previous standard treatments. EXPERIMENTAL

designThirty-one patients with measurable metastatic GIST who failed both imatinib and sunitinib were accrued. Sorafenib was administered orally at 400 mg twice daily until disease progression or development of intolerance. The primary endpoint was disease control rate (response + stable disease, DCR) at 24 weeks.

resultsSorafenib was well tolerated, with hand-foot skin reaction, fatigue, hypertension, and abdominal pain being the most frequent adverse events. The relative dose intensity of sorafenib during the first 6 months was >80%. Four patients achieved partial response (response rate 13%, 95% CI 1-25%), and 16 (52%) had stable disease. DCR at 24 weeks was measured as 36% (95% CI 19-52%). Median progression-free and overall survivals were 4.9 and 9.7 months, respectively. Progression-free survival of patients with prior use of nilotinib (P = .0085) and with primary genotypes other than KIT exon 11 mutation (P = .0341) was significantly shorter than that of patients without.

conclusionsSorafenib showed antitumor activity in this population of imatinib and sunitinib pretreated GIST. With sorafenib, about one third of patients can maintain disease control for more than 24 weeks.

Indexed as

AdultAgedAntineoplastic AgentsAsian PeopleDrug Resistance, NeoplasmFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsGenotypeHumansMaleMiddle AgedMutationNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsAntineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaSorafenib

Identifiers

PMID22270258
OpenAlexW2076516630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.